Preclinical Alzheimer’s Disease: Definition, Natural History, and Diagnostic Criteria

Cites (298)

Items 201–298 of 298

1. Effects of Age, Sex, and Ethnicity on the Association Between Apolipoprotein E Genotype and Alzheimer Disease: A Meta-analysis
   Farrer, Lindsay A. · 1997 · JAMA
2. Methodological challenges in designing dementia prevention trials—the European Dementia Prevention Initiative (EDPI)
   Richard, Edo, Andrieu, Sandrine, Solomon, Alina, Mangialasche, Francesca, Ahtiluoto, Satu, van Charante, Eric P. Moll, Coley, Nicola, Fratiglioni, Laura, Neely, Anna Stigsdotter, Vellas, Bruno et al. · 2012 · Journal of the Neurological Sciences
3. Concordance Between Cerebrospinal Fluid Biomarkers and [11C]PIB PET in a Memory Clinic Cohort
   Marissa Deborah Zwan, Argonde C. van Harten, Rik Ossenkoppele, Femke H. Bouwman, Charlotte Elisabeth Teunissen, Sofie F. Adriaanse, Adriaan A. Lammertsma, Philip Scheltens, Bart N.M. van Berckel, Wiesje M. van der Flier · 2014 · Journal of Alzheimer s Disease
4. Diagnosis and management of Alzheimer's disease: Past, present and future ethical issues
   Serge G. Gauthier, Antoine Leuzy, Éric Racine, Pedro Rosa‐Neto · 2013 · Progress in Neurobiology
5. Screening for predementia AD
   Carol A. Derby, Leah C. Burns, Cuiling Wang, Mindy Joy Katz, Molly E. Zimmerman, Gilbert L’Italien, Zhenchao Guo, Robert Berman, Richard B. Lipton · 2013 · Neurology
6. A blood-based predictor for neocortical Aβ burden in Alzheimer’s disease: results from the AIBL study
   Samantha C. Burnham, Noel Garry Faux, W.J. Wilson, Simon Matthew Laws, David J. Ames, Justin Bedő, Ashley Ian Bush, James D. Doecke, Kathryn A. Ellis, Richard J. Head et al. · 2013 · Molecular Psychiatry
7. Reduced FDG-PET brain metabolism and executive function predict clinical progression in elderly healthy subjects
   Michael Ewers, Matthias Brendel, Angela Rizk‐Jackson, Axel Rominger, Peter Bartenstein, Norbert W. Schuff, Michael Walter Weiner · 2013 · NeuroImage Clinical
8. Apolipoprotein E: Implications for AD neurobiology, epidemiology and risk assessment
   Hyman M. Schipper · 2009 · Neurobiology of Aging
9. Cognitively Preserved Subjects with Transitional Cerebrospinal Fluid ß-Amyloid 1-42 Values Have Thicker Cortex in Alzheimer's Disease Vulnerable Areas
   Juan Fortea, Roser Sala‐Llonch, David Bartrés‐Faz, Albert Lladó, Cristina Solé‐Padullés, Beatríz Bosch, Anna Antonell, Jaume Olives, Raquel Sánchez‐Valle, José Luís Molinuevo et al. · 2011 · Biological Psychiatry
10. Commentary on “A roadmap for the prevention of dementia II. Leon Thal Symposium 2008.” The Multidomain Alzheimer Preventive Trial (MAPT): A new approach to the prevention of Alzheimer's disease
    Sophie Guyonnet, Sandrine Andrieu, THIERRY F. DANTOINE, Jean‐François Dartigues, Jacques Touchon, Bruno J. Vellas, MAPT Study Group · 2009 · Alzheimer s & Dementia
11. Cortical event-related potentials in preclinical familial Alzheimer disease
    Edward J. Golob, John Matthew Ringman, Rie Irimajiri, S. Bright, Barbara Schaffer, Luis Daniel Medina, Arnold Starr · 2009 · Neurology
12. Biomarkers in Sporadic and Familial Alzheimer’s Disease
    Lista, Simone, O’Bryant, Sid E., Blennow, Kaj, Dubois, Bruno, Hugon, Jacques, Zetterberg, Henrik, Hampel, Harald · 2015 · Journal of Alzheimer's Disease
13. Characteristics of the default mode functional connectivity in normal ageing and Alzheimer's disease using resting state fMRI with a combined approach of entropy-based and graph theoretical measurements
    Paule‐Joanne Toussaint, Sofiane Maiz, David Coynel, Julien Doyon, Arnaud Messé, Leonardo Cruz de Souza, Marie Sarazin, Vincent Perlbarg, Marie‐Odile Habert, Habib Benali · 2014 · NeuroImage
14. Altered Oscillation and Synchronization of Default-Mode Network Activity in Mild Alzheimer’s Disease Compared to Mild Cognitive Impairment: An Electrophysiological Study
    Fu‐Jung Hsiao, Yuh-Jen Wang, Sui‐Hing Yan, Wei‐Ta Chen, Yung‐Yang Lin · 2013 · PLoS ONE
15. The effect of apolipoprotein E (ApoE) genotype on biomarkers of amyloidogenesis, tau pathology and neurodegeneration in Alzheimer's disease
    Valerio Leoni · 2011 · Clinical Chemistry and Laboratory Medicine (CCLM)
16. Functional MRI Assessment of Task-Induced Deactivation of the Default Mode Network in Alzheimer’s Disease and At-Risk Older Individuals
    Pihlajamäki, Maija, Sperling, Reisa A. · 2009 · Behavioural Neurology
17. The moral challenge of Alzheimer disease
    Stephen Garrard Post · 1996 · Choice Reviews Online
18. Classification of amyloid-positivity in controls: Comparison of visual read and quantitative approaches
    Ann D. Cohen, Wenzhu Bi Mowrey, Lisa A. Weissfeld, Howard Jay Aizenstein, Eric McDade, James M. Mountz, Robert D. Nebes, Judith A. Saxton, Beth Ellen Snitz, Steven Trent DeKosky et al. · 2013 · NeuroImage
19. Effect of Cognitive Reserve Markers on Alzheimer Pathologic Progression
    Raymond Y. Lo, William J. Jagust · 2013 · Alzheimer Disease & Associated Disorders
20. Instrumental activities of daily living among community-dwelling older adults: Discrepancies between self-report and performance are mediated by cognitive reserve
    Yana Suchy, Matthew Kraybill, Emilie I. Franchow · 2010 · Journal of Clinical and Experimental Neuropsychology
21. Favorite music and hand massage
    Sandee L. Hicks-Moore, Bryn Robinson · 2008 · Dementia
22. Functional MRI assessment of task-induced deactivation of the default mode network in Alzheimer's disease and at-risk older individuals.
    Maija M. Pihlajamaki, Reisa Anne Sperling · 2009 · PubMed
23. Neuronal injury biomarkers and prognosis in ADNI subjects with normal cognition
    Toledo, Jon B, Weiner, Michael W, Wolk, David A, Da, Xiao, Chen, Kewei, Arnold, Steven E, Jagust, William, Jack, Clifford, Reiman, Eric M, Davatzikos, Christos et al. · 2014 · Acta Neuropathologica Communications
24. Trajectories of memory decline in preclinical Alzheimer's disease: results from the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing
    Robert H. Pietrzak, Yen Ying Lim, David J. Ames, Karra Harrington, Carolina Restrepo, Ralph Nigel Martins, Alan Rembach, Simon Matthew Laws, Colin Louis Masters, Victor L. Villemagne et al. · 2014 · Neurobiology of Aging
25. Early behavioural changes in familial Alzheimer’s disease in the Dominantly Inherited Alzheimer Network
    John Matthew Ringman, Li-Jung Liang, Yan Feng Zhou, Sitaram Vangala, Edmond Teng, Sarah A. Kremen, David Wharton, Alison Goate, Daniel S. Marcus, Martin Rhys Farlow et al. · 2015 · Brain
26. Validation of a Serum Screen for Alzheimer's Disease Across Assay Platforms, Species, and Tissues
    Sid E. O’Bryant, Guanghua Xiao, Fan Zhang, Melissa Edwards, Dwight C. German, Xiangling Yin, Tori Como, Joan Reisch, Ryan M. Huebinger, Neill R. Graff‐Radford et al. · 2014 · Journal of Alzheimer s Disease
27. APOE ε4 moderates amyloid-related memory decline in preclinical Alzheimer's disease
    Yen Ying Lim, Victor L. Villemagne, Robert H. Pietrzak, David J. Ames, Kathryn A. Ellis, Karra Harrington, Peter Jeffrey Snyder, Ralph Nigel Martins, Colin Louis Masters, Christopher C. Rowe et al. · 2014 · Neurobiology of Aging
28. Injury Markers but not Amyloid Markers are Associated with Rapid Progression from Mild Cognitive Impairment to Dementia in Alzheimer's Disease
    Ineke A. van Rossum, Pieter Jelle Visser, Dirk L. Knol, Wiesje M. van der Flier, Charlotte Elisabeth Teunissen, Frederik Barkhof, Marinus A. Blankenstein, Philip Scheltens · 2012 · Journal of Alzheimer s Disease
29. Evidence that volume of anterior medial temporal lobe is reduced in seniors destined for mild cognitive impairment
    Sarah B. Martin, Charles D. Smith, Heather R. Collins, F.A. Schmitt, Brian T. Gold · 2008 · Neurobiology of Aging
30. Selective Disruption of the Cerebral Neocortex in Alzheimer's Disease
    Rahul S. Desikan, Mert Rory Sabuncu, Nicholas J. Schmansky, Martin Reuter, Howard Cabral, Christopher Paul Hess, Michael Walter Weiner, Alessandro Biffi, Christopher D. Anderson, Jonathan M. Rosand et al. · 2010 · PLoS ONE
31. Comparison of Visual and Quantitative Florbetapir F 18 Positron Emission Tomography Analysis in Predicting Mild Cognitive Impairment Outcomes
    Stefanie Schreiber, Susan M. Landau, Allison Fero, Frank Schreiber, William J. Jagust · 2015 · JAMA Neurology
32. Effect of Alzheimer disease genetic risk disclosure on dietary supplement use
    Jacqueline A. Vernarelli, Jeffrey Scott Roberts, Susan C. Hiraki, Clara A. Chen, L. Adrienne Cupples, Robert C. Green · 2010 · American Journal of Clinical Nutrition
33. Prevention trials in Alzheimer's disease: An EU-US task force report
    Bruno J. Vellas, Paul S. S Aisen, Cristina Sampaio, María C. Carrillo, Philip Scheltens, Bruno Scherrer, Giovanni Battista Frisoni, Michael Walter Weiner, Lon S. S. Schneider, Serge G. Gauthier et al. · 2011 · Progress in Neurobiology
34. CSF Aβ1‐42 combined with neuroimaging biomarkers in the early detection, diagnosis and prediction of Alzheimer's disease
    Simone Lista, Francesco Garaci, Michael Ewers, Stefan Johannes Teipel, Henrik Zetterberg, Kaj Blennow, Harald Juergen Hampel · 2013 · Alzheimer s & Dementia
35. Tau pathology in children and young adults: can you still be unconditionally baptist?
    Charles J. Duyckaerts · 2011 · Acta Neuropathologica
36. Reference Measurement Procedures for Alzheimer’s Disease Cerebrospinal Fluid Biomarkers: Definitions and Approaches With Focus on Amyloid β42
    Niklas Mattsson, Ingrid Zegers, Ulf Andréasson, Maria Bjerke, Marinus A. Blankenstein, Robert P. Bowser, María C. Carrillo, Johan Gobom, Theresa Heath, Rand G Jenkins et al. · 2012 · Biomarkers in Medicine
37. Are subjective cognitive complaints a risk factor for dementia?
    R. Gallassi, Federico Oppi, Roberto Poda, Simona Scortichini, Michelangelo Stanzani Maserati, Gianfranco Marano, Luisa Sambati · 2010 · Neurological Sciences
38. A quantitative histological study of early clinical and preclinical Alzheimer's disease
    Bethan M. Hubbard, G. W. FENTONM, J. McRay Anderson · 1990 · Neuropathology and Applied Neurobiology
39. Public Perceptions of Presymptomatic Testing for Alzheimer Disease
    Richard J. Caselli, Jessica B. S. Langbaum, Gary E. Marchant, Rachel A. Lindor, Katherine S. Hunt, Bruce R. Henslin, Amylou Constance Dueck, Jason Scott Robert · 2014 · Mayo Clinic Proceedings
40. Standardization of Assay Procedures for Analysis of the CSF Biomarkers Amyloid β(1-42) , Tau, and Phosphorylated Tau in Alzheimer's Disease: Report of an International Workshop
    Charlotte Elisabeth Teunissen, Niek A. Verwey, Maartje I. Kester, Kees W. J. van Uffelen, Marinus A. Blankenstein · 2010 · International Journal of Alzheimer s Disease
41. Preclinical AD Workgroup staging: Pathological correlates and potential challenges
    Jicha, Gregory A., Abner, Erin L., Schmitt, Frederick A., Kryscio, Richard J., Riley, Kathryn P., Cooper, Gregory E., Stiles, Nancy, Mendiondo, Marta S., Smith, Charles D., Van Eldik, Linda J. et al. · 2012 · Neurobiology of Aging
42. Enrichment and Stratification for Predementia Alzheimer Disease Clinical Trials
    Dominic Holland, Linda K. McEvoy, Rahul S. Desikan, Anders Martin Dale, Alzheimer’s Disease Neuroimaging Initiative · 2012 · PLoS ONE
43. CSF Apo-E levels associate with cognitive decline and MRI changes
    For the Alzheimer’s Disease Neuroimaging Initiative, Toledo, Jon B., Da, Xiao, Weiner, Michael W., Wolk, David A., Xie, Sharon X., Arnold, Steven E., Davatzikos, Christos, Shaw, Leslie M., Trojanowski, John Q. · 2014 · Acta Neuropathologica
44. The effect of amyloid β on cognitive decline is modulated by neural integrity in cognitively normal elderly
    Miranka Wirth, Hwamee Oh, Elizabeth C. Mormino, Candace Markley, Susan M. Landau, William J. Jagust · 2013 · Alzheimer s & Dementia
45. Physical Activity, Mediterranean Diet and Biomarkers-Assessed Risk of Alzheimer’s: A Multi-Modality Brain Imaging Study
    Dawn C. Matthews, Michelle Davies, John Murray, Schantel Williams, Wai Hon Tsui, Yi Li, Randolph D. Andrews, Ana Lukic, Pauline F. McHugh, Shankar Vallabhajosula et al. · 2014 · Advances in Molecular Imaging
46. Distinct Functional Activity of the Precuneus and Posterior Cingulate Cortex During Encoding in the Preclinical Stage of Alzheimer's Disease
    Lorena Rami, Roser Sala‐Llonch, Cristina Solé‐Padullés, Juan Fortea, Jaume Olives, Albert Lladó, Cleofé Peña-Gómez, Mircea Balasa, Beatríz Bosch, Anna Antonell et al. · 2012 · Journal of Alzheimer s Disease
47. Medial temporal atrophy in early and late-onset Alzheimer's disease
    Enrica Cavedo, Michela Pievani, Marina Boccardi, Samantha Galluzzi, Martina Bocchetta, Matteo Bonetti, Paul M. Thompson, Giovanni Battista Frisoni · 2014 · Neurobiology of Aging
48. The rising global tide of cognitive impairment
    Harald Juergen Hampel, Simone Lista · 2016 · Nature Reviews Neurology
49. Comparison of the severity of neuropathologic changes in familial and sporadic Alzheimer's disease.
    David Nochlin, Gerald van Belle, Thomas D. Bird, S. M. Sumi · 1993 · PubMed
50. Prefrontal cortex atrophy predicts dementia over a six-year period
    Saartje Burgmans, Martin P.J. van Boxtel, Floortje Smeets, Eric F. P. M. Vuurman, E. H. B. M. Gronenschild, Frans R.J. Verhey, Harry B. M. Uylings, Jelle Jolles · 2008 · Neurobiology of Aging
51. Phenomenological characterization of memory complaints in preclinical and prodromal Alzheimer’s disease.
    Rachel F. Buckley, Kathryn A. Ellis, David J. Ames, Christopher C. Rowe, Nicola T. Lautenschlager, Paul T. Maruff, Victor L. Villemagne, S. Lance Macaulay, Cassandra E. I. Szoeke, Ralph Nigel Martins et al. · 2015 · Neuropsychology
52. Advances and perspectives from genetic research: development of biological markers in Alzheimer’s disease
    Thomas Zetzsche, Dan Rujescu, John Hardy, Harald Juergen Hampel · 2010 · Expert Review of Molecular Diagnostics
53. Approaching clinical proteomics: Current state and future fields of application in cellular proteomics
    Rolf Apweiler, Charalampos Aslanidis, Thomas Deufel, Andreas O. H. Gerstner, Jens Hansen, D. F. Hochstrasser, Roland Kellner, Markus Kubicek, Friedrich Lottspeich, Edmund Maser et al. · 2009 · Cytometry Part A
54. Preclinical Alzheimer disease: identification of cases at risk among cognitively intact older individuals
    Maciej Jakub Lazarczyk, Patrick R. Hof, Constantin Bouras, Pantéleimon Giannakopoulos · 2012 · BMC Medicine
55. Prediction of Preclinical Alzheimer's Disease: Longitudinal Rates of Change in Cognition
    Kathryn Perez Riley, Gregory A. Jicha, Daron G. Davis, Erin L. Abner, Gregory E. Cooper, Nancy J. Stiles, Charles D. Smith, Richard J. Kryscio, Peter T. Nelson, Linda J. Van Eldik et al. · 2011 · Journal of Alzheimer s Disease
56. Eyes-closed task-free electroencephalography in clinical trials for Alzheimer’s disease: an emerging method based upon brain dynamics
    Elisabeth C.W. van Straaten, Philip Scheltens, Alida A. Gouw, Cornelis Jan Stam · 2014 · Alzheimer s Research & Therapy
57. Cerebrospinal Fluid Biomarkers, Education, Brain Volume, and Future Cognition
    Catherine M. Roe, Anne M. Fagan, Elizabeth Grant, Daniel S. Marcus, Tammie L.S. Benzinger, Mark A. Mintun, David M. Holtzman, John C. Morris · 2011 · Archives of Neurology
58. Event-related potential markers of brain changes in preclinical familial Alzheimer disease
    Yakeel T. Quiroz, Brandon A. Ally, Kim Celone, Joshua D. McKeever, Adriana L. Ruiz‐Rizzo, Francisco Javier Lopera, Chantal E. Stern, Andrew E. Budson · 2011 · Neurology
59. MEG Connectivity Analysis in Patients with Alzheimer’s Disease Using Cross Mutual Information and Spectral Coherence
    Joan Francesc Alonso, Jesús Poza, Miguel Ángel Mañanas, Sergio Romero, Alberto Fernández, Roberto Hornero · 2010 · Annals of Biomedical Engineering
60. Brain amyloidosis ascertainment from cognitive, imaging, and peripheral blood protein measures
    Liana G. Apostolova, Kristy Hwang, David Avila, David A. Elashoff, Omid Kohannim A, Edmond Teng, Sophie Sokolow, Clifford R. Jack, William Jagust, Leslie M. J. Shaw et al. · 2015 · Neurology
61. Alzheimer's disease therapeutic trials: EU/US task force report on recruitment, retention, and methodology
    Bruno J. Vellas, Harald Juergen Hampel, Marie-Ève Rougé Bugat, Michael Grundman, Sandrine Andrieu, Susan R. Abushakra, Randall John Bateman, Robert Berman, Ronald S. Black, María C. Carrillo et al. · 2012 · The journal of nutrition health & aging
62. Alterations in Tau Protein Metabolism during Normal Aging
    EB Mukaetova-Ladinska, Charles R. Harrington, Martin Roth, Claude M. Wischik · 1996 · Dementia and Geriatric Cognitive Disorders
63. Psychomotor Retardation in Elderly Untreated Depressed Patients
    Lieve Lia Beheydt, Didier L. Schrijvers, Lise Docx, Filip Bouckaert, Wouter Hulstijn, Bernard Sabbe · 2015 · Frontiers in Psychiatry
64. The P300 component in patients with Alzheimer's disease and their biological children
    Brandon A. Ally, Gary E. Jones, Jack A. Cole, Andrew E. Budson · 2005 · Biological Psychology
65. Risk disclosure and preclinical Alzheimer's disease clinical trial enrollment
    Joshua D. Grill, Jason H. Karlawish, David A. Elashoff, Barbara G. Vickrey · 2012 · Alzheimer s & Dementia
66. From inherited to sporadic AD—crossing the biomarker bridge
    Harald Juergen Hampel, Simone Lista · 2012 · Nature Reviews Neurology
67. Evaluation and Use of Diagnostic Tests in Alzheimer’s Disease
    Richard P Mayeux · 1998 · Neurobiology of Aging
68. Subjective Cognitive Complaints in Parkinson Disease Without Dementia: A Preliminary Study
    Daniel P. Koster, Christopher I. Higginson, Elizabeth E. MacDougall, Vicki Wheelock, Karen A. Sigvardt · 2014 · Applied Neuropsychology Adult
69. Multiplex biomarkers in blood
    Veer Bala Gupta, Ramani Sundaram, Ralph Nigel Martins · 2013 · Alzheimer s Research & Therapy
70. Alzheimer disease: From biomarkers to diagnosis
    Bruno Dubois, Stéphane Epelbaum, Ana Santos, Francesca Di Stefano, Ana Guinovart Julian, Agnès Michon, Marie Sarazin, Harald Juergen Hampel · 2013 · Revue Neurologique
71. Cerebrospinal fluid markers for Alzheimer's disease in a cognitively healthy cohort of young and old adults
    Donata Paternicò, Samantha Galluzzi, Valeria Drago, Luisella Bocchio‐Chiavetto, Roberta Zanardini, Laura Pedrini, Manuela Baronio, Giovanni Amicucci, Giovanni Battista Frisoni · 2012 · Alzheimer s & Dementia
72. Early Indications of Future Cognitive Decline: Stable versus Declining Controls
    Angela Rizk‐Jackson, Philip S. Insel, Ronald Carl Petersen, Paul S. S Aisen, Clifford R. Jack, Michael Walter Weiner · 2013 · PLoS ONE
73. Neuroimaging biomarkers for Alzheimer's disease in asymptomatic APOE4 carriers
    Gaël Chételat, Marine Fouquet · 2013 · Revue Neurologique
74. A multi-center, randomized, double blind placebo-controlled trial of estrogens to prevent Alzheimer's disease and loss of memory in women: design and baseline characteristics
    Mary C. Sano, Diane M. Jacobs, Howard Andrews, Karen L. Bell, Neill R. Graff‐Radford, John Alexander Lucas, Peter V. Rabins, Karen I. Bolla, Wei-Yan Tsai, Peter S. Cross et al. · 2008 · Clinical Trials
75. Biomarkers in clinical trials for neurodegenerative diseases: Regulatory perspectives and requirements
    Karl Broich, Marco Weiergräber, Harald Juergen Hampel · 2011 · Progress in Neurobiology
76. A conceptual framework and ethics analysis for prevention trials of Alzheimer Disease
    Kevin R. Peters, B. Lynn Beattie, Howard Feldman, Judy Illes · 2013 · Progress in Neurobiology
77. CSF biomarkers of Alzheimer disease
    Catherine M. Roe, Anne M. Fagan, Elizabeth Grant, David M. Holtzman, John C. Morris · 2013 · Neurology
78. Use of biomarkers and imaging to assess pathophysiology, mechanisms of action and target engagement
    Harald Juergen Hampel, Simone Lista · 2013 · The journal of nutrition health & aging
79. The relative efficiency of time-to-threshold and rate of change in longitudinal data
    Michael Donohue, Anthony C. Gamst, Ronald G. Thomas, Ronghui Xu, Laurel A. Beckett, Ronald Carl Petersen, Michael Walter Weiner, Paul S. S Aisen · 2011 · Contemporary Clinical Trials
80. The role of genetics for biomarker development in neurodegeneration
    Lars Bertram, Harald Juergen Hampel · 2011 · Progress in Neurobiology
81. Mapping Out Biomarkers for Alzheimer Disease
    Monique M.B. Breteler · 2011 · JAMA
82. Cerebrospinal Fluid Biomarkers in Alzheimer’s Disease Families with PSEN1 Mutations
    Juan Fortea, Albert Lladó, Beatríz Bosch, Anna Antonell, Rafael Oliva, José Luís Molinuevo, Raquel Sánchez‐Valle · 2011 · Neurodegenerative Diseases
83. Ethical Guidelines of the Alzheimer Society of Canada
    John D. Fisk, Adele Dessa Sadovnick, Carole A. Cohen, Serge G. Gauthier, John B. Dossetor, Astrid Eberhart, Linda Leduc · 1998 · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques
84. Alzheimer's disease: identical phenotype of familial and non-familial cases
    Martin Haupt, Alexander Kurz, Stefan Pollmann, Bárbara Romero · 1992 · Journal of Neurology
85. Secondary Prevention Trials in Alzheimer Disease
    Richard J. Kryscio · 2014 · JAMA Neurology
86. Toward onset prevention of cognitive decline in adults with Down syndrome (the TOP-COG study): study protocol for a randomized controlled trial
    Sally‐Ann Cooper, MURIEL J. CASLAKE, Jonathan J. Evans, Angela Hassiotis, Andrew J. Jahoda, Alex McConnachie, Jill Morrison, HOWARD A. RING, John M. Starr, Ciara Stiles et al. · 2014 · Trials
87. Amyloid + Activation = Alzheimer's?
    William J. Jagust · 2009 · Neuron
88. Presymptomatic apolipoprotein E genotyping for Alzheimer's disease risk assessment and prevention
    Hyman M. Schipper · 2011 · Alzheimer s & Dementia
89. The clinical phenotype of familial and sporadic late onset Alzheimer's disease
    Clive Holmes, Simon Lovestone · 2002 · International Journal of Geriatric Psychiatry
90. Potential sources of interference on Abeta immunoassays in biological samples
    Hugo Vanderstichele, Erik Stoops, Eugeen Vanmechelen, Andreas Jeromin · 2012 · Alzheimer s Research & Therapy
91. Combining Select Neuropsychological Assessment with Blood-Based Biomarkers to Detect Mild Alzheimer's Disease: A Molecular Neuropsychology Approach
    Melissa Edwards, Valerie Hobson Balldin, James Richard Hall, Sid E. O’Bryant · 2014 · Journal of Alzheimer s Disease
92. P4–344: Candidate blood proteome markers of Alzheimer's disease onset and progression: A systematic review and replication study
    Chantal E. Bazenet, Steven John Kiddle, Martina Sattlecker, Petroula Proitsi, Andrew Simmons, Eric Westman, Sally Nelson, David Sterling, Steven Williams, Angela Hodges et al. · 2013 · Alzheimer s & Dementia
93. What is a Certified Reference Material?
    Niklas Mattsson, Henrik Zetterberg · 2012 · Biomarkers in Medicine
94. Influences of APOE ε4 and expertise on performance of older pilots.
    Joy L. Taylor, Quinn Kennedy, Maheen M. Adamson, Laura C. Lazzeroni, Art M. Noda, Greer M. Murphy, Jerome Albert Yesavage · 2011 · Psychology and Aging
95. Elderly women with larger social networks are less likely to develop dementia
    Robert S. Wilson · 2009 · Evidence-Based Mental Health
96. A safety test for Eastern equine encephalomyelitis vaccine
    Sanford Berman, Joseph P. Lowenthal, James V. Sorrentino, AD White · 1967 · Applied Microbiology
97. [Familial forms of Alzheimer's disease].
    Lucie Guyant‐Maréchal, Dominique Campion, Didier Hannequin · 2003 · PubMed
98. Side-Effects of Rinsing Fluids on the Rat Femoral Artery
    Olivier P. Delaere, U Mennen, Willie F. P. van Heerden, Erich J. Raubenheimer, A.M.J. Wiese, D. Boomker · 1997 · Journal of Hand Surgery (European Volume)